MEDP stock forecast, quote, news & analysis
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms... Show more
Why Medpace Holdings (MEDP) Is Up +10% in the Last 30 Days
Key Takeaways
- MEDP stock rose +10% over the last 30 days, driven by positive analyst sentiment and anticipation ahead of quarterly earnings.
- The stock experienced volatility, dipping to a recent low before recovering strongly in recent trading sessions.
- Over the past quarter, shares declined -7%, primarily due to a post-earnings selloff amid concerns over trial cancellations and backlog normalization.
- Strong fundamentals, including consistent EPS beats, support recovery potential in the clinical research sector.
- Analyst price target increases reflect optimism about revenue growth from oncology and metabolic trials.
Medpace Holdings (MEDP) Company Overview and Market Position
Medpace Holdings, Inc. (MEDP) is a leading contract research organization (CRO) that provides full-service clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company focuses on late-stage drug development, managing clinical trials from Phase I through regulatory approval. Its asset-light model emphasizes operational efficiency, enabling it to serve small- and mid-sized biotech firms that lack in-house capabilities. In a competitive CRO landscape dominated by giants like IQVIA and PPD, Medpace differentiates through its specialized expertise in oncology and rare diseases, which has driven consistent backlog growth and supports its recent stock price resilience amid sector headwinds.
Medpace Holdings (MEDP) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, MEDP stock climbed +10%, moving from a close of $480.19 to $528.44. The price action was volatile, with a low of $451.20 earlier in the period before a steady rebound.
In contrast, the past quarter saw a net decline of approximately -7%, from around $571 in early January to the current level. Shares peaked near $621 mid-quarter but faced significant downward pressure, hitting a low near $451 before partial recovery. This range-bound yet trend-driven movement highlights sensitivity to company-specific news amid broader market trends.
What Drove MEDP Stock Price in the Last 30 Days
The recent +10% uptick in MEDP's stock price stems from renewed investor confidence ahead of Q1 earnings, coupled with analyst upgrades. Firms raised price targets to as high as $579, citing robust demand in key therapeutic areas. Positive sector sentiment, with healthcare stocks averaging 9% gains, also bolstered the rally as biopharma funding concerns eased. The stock outperformed the broader market on multiple days, lapping the S&P 500 amid steady volume. These factors reversed earlier March weakness, driving a trend recovery.
What Drove MEDP Stock Performance Over the Last Quarter
MEDP shares declined -7% over the quarter, largely triggered by the Q4 earnings release in February, where revenue beat estimates but disclosures on trial cancellations and shifting backlog dynamics sparked selling. Management highlighted normalization in backlog alongside a pivot toward metabolic trials, tempering growth outlook for 2026 at up to 12.8%. This led to a sharp post-earnings drop of nearly 16%, exacerbated by broader biopharma sector worries over funding. Macro factors like interest rate sensitivity in biotech also weighed, though competitive positioning in high-demand oncology trials provided some cushion. Institutional flows remained mixed, with cumulative impact from earnings sentiment dominating.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. These curated bots are selected based on recent performance metrics, relevance to current market trends, and strategy diversity, including momentum, mean reversion, and machine learning-driven approaches. Timeframes range from intraday to long-term holds, with transparency on win rates, Sharpe ratios, and drawdowns. Investors can explore, backtest, and deploy these bots to enhance their trading strategies—check out the page to discover bots tailored to stocks like MEDP.
MEDP Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor upcoming Q1 earnings for updates on backlog trends, cancellation rates, and guidance amid ongoing shifts in metabolic and oncology trials. Industry developments, such as biopharma R&D spending and regulatory changes, could influence demand for CRO services. Macroeconomic factors like interest rates and inflation impacting biotech funding remain key. Strategic moves in partnerships or expansions, alongside analyst revisions, will shape sentiment. Risks include further trial delays, while catalysts may arise from beats on revenue or EPS.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
MEDP in upward trend: 10-day moving average moved above 50-day moving average on June 11, 2026
The 10-day moving average for MEDP crossed bullishly above the 50-day moving average on June 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 21, 2026. You may want to consider a long position or call options on MEDP as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MEDP just turned positive on May 14, 2026. Looking at past instances where MEDP's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .
MEDP moved above its 50-day moving average on June 08, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MEDP advanced for three days, in of 326 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 251 cases where MEDP Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for MEDP moved out of overbought territory on June 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MEDP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MEDP broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MEDP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.321) is normal, around the industry mean (12.221). P/E Ratio (29.411) is within average values for comparable stocks, (140.227). MEDP's Projected Growth (PEG Ratio) (2.873) is slightly higher than the industry average of (1.506). MEDP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (5.056) is also within normal values, averaging (7.228).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company
Industry MedicalSpecialties